Gene Therapy for Longevity & Heart Health: Entering Clinical Trials | Dr Noah Davidsohn - Clip

Rejuvenate Bio, co-founded by today’s guest Dr. Noah Davidsohn, develops one-time gene therapies that target the root causes of aging and age-related disease. A single injection reversed cardiac disease in dogs, with three years of safety data and zero safety signals. Animal health partners fund the science, with $130M+ in contracted milestones across six partnerships, while the platform advances toward human trials. Merck Animal Health joined as an investor and R&D collaborator in their $6M round led by VCapital. Their community round on Wefunder is closing soon. Invest now: https://tinyurl.com/593bb72c Join us as Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio, explains how a single liver-directed gene therapy could protect against heart disease, metabolic decline, and age-related illness for over 10 years. Discover how FGF21 and anti-TGF-beta-1 turn the liver into an anti-aging protein biofactory with zero genomic integration. Can a single 10-minute gene therapy infusion protect against heart failure and metabolic decline for a decade? In this clip, Dr. Noah Davidsohn, CSO and Co-Founder of Rejuvenate Bio (spun out of George Church's lab at Harvard Medical School), breaks down their breakthrough preclinical and veterinary trial data. Dr. Davidsohn shares how their lead therapy extended the lifespan of dogs with mitral valve disease by 1 to 2 years (equivalent to approximately 14 human years) from a single 10-minute infusion. He also details their upcoming human trial targeting FGF21, a starvation hormone that provides robust cardiac protection, optimizes calcium and sodium signaling, and drives metabolic improvements superior to GLP-1 without reducing food intake. Learn how turning the liver into an internal biofactory delivers non-integrating, long-term multi-organ protection. 📚 Chapters 00:00 Canine Trial: 2 Extra Years of Life from 1 Shot 04:28 FGF21: Better Than GLP-1 for Heart & Metabolism 06:24 Turning the Liver into an Anti-Aging Biofactory 09:05 10-Year Protection from a Single Non-Integrating Dose 🔬 Scientific Citations & References Mentioned 1. Davidsohn, N., et al. (2019). A single systemic gene therapy delivery of FGF21 and sTGFbetaR2 simultaneously treats multiple age-related diseases in mice. Proceedings of the National Academy of Sciences (PNAS). 2. Rejuvenate Bio Preclinical Pipeline Data: RJB-01 & Companion Animal MMVD Trials. 🌐 Links in this video: - Rejuvenate Bio Website: https://www.rejuvenatebio.com Medical Disclaimer: The content of this video is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any changes to your health regimen, supplement stack, or undertaking medical therapies. #Longevity #GeneTherapy #FGF21 #HeartHealth #RejuvenateBio #AntiAging #Healthspan #GeorgeChurch #Biotech #ModernHealthspan